Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

Obesity Research

Volumn 10, Issue 10, 2002, Pages 1049-1056

  Jain, Adesh K ^a,g   Kaplan, Roy A ^b   Gadde, Kishore M ^c   Wadden, Thomas A ^d   Allison, David B ^e   Brewer, Edwin R ^f   Leadbetter, Robert A ^f   Richard, Nathalie ^f   Haight, Barbara ^f   Jamerson, Brenda D ^f   Buaron, Kathleen S ^f   Metz, Alan ^f  

^a Medical Research Institute   (United States)

^b East Bay Clinical Trial Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f GLAXOSMITHKLINE   (United States)

^g Medical Research Institute Inc   (United States)

Author keywords

Anorexigens; Antidepressant; Bupropion sustained release; Clinical trial; Depression

Indexed keywords

AMFEBUTAMONE; CHOLESTEROL; DOPAMINE UPTAKE INHIBITOR; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DEPRESSION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEEDING BEHAVIOR; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; LOW CALORY DIET; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BUPROPION; CHOLESTEROL; DELAYED-ACTION PREPARATIONS; DEPRESSION; DIET, REDUCING; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEEDING BEHAVIOR; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; OBESITY; TRIGLYCERIDES; WEIGHT LOSS;

EID: 0036778351     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2002.142     Document Type: Article

References (21)

1. Khaodhiar L, McCowen KC, Blackburn GL. Obesity and its comorbid conditions. Clin Cornerstone. 1999;2:17-31.
2. Lamberg L. Psychiatric help may shrink some waistlines. JAMA. 2000;284:291-3.
3. Fitzgibbon ML, Stolley MR, Kirschenbaum DS. Obese people who seek treatment have different characteristics than those who do not seek treatment. Health Psychol. 1993;12:342-5.
4. Wadden TA, Womble LG, Stunkard AJ, Anderson DA. Psychosocial consequences of obesity and weight loss. In: Wadden TA, Stunkard AJ, eds. Handbook of Obesity Treatment. New York: The Guilford Press; 2002, pp. 144-169.
5. Anderson JW, Greenway F, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633-41.
6. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544-51.
7. Croft H, Houser T, Jamerson B, et al. Effect on body weight of bupropion sustained release in patients with major depression treated for 52 weeks. Clin Ther. 2002;24:662-72.
8. Steer RA, Ball R, Ranieri WF, Beck AT. Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Clin Psychol. 1999;55:117-28.
9. th ed. Washington, DC: American Psychiatric Association; 1994, pp. 317-345.
10. World Health Organization. Energy and protein requirements. WHO Technical Report Series. Geneva, Switzerland: World Health Organization; 1985.
11. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory, 2nd ed. San Antonia, TX: The Psychological Corporation.
12. Stahl SM. Basic psychopharmacology of antidepressants. Part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatr. 1998;59(Suppl 4):5-14.
13. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatr. 1998;59(Suppl 18):23-9.
14. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Molec Neurobiol. 1999;19:467-89.
15. Samanin R, Garattini S. Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol. 1993;73:63-8.
16. Hopkinson G. A neucochemical theory of appetite and weight changes in depressive states. Acta Psychiatr Scand. 1981;64: 217-25.
17. Jorenby D, Leischow S, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-92.
18. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained-release and sertraline in depressed outpatients. J Clin Psychiatr. 1997;58:532-7.
19. Weihs KL, Settle EC, Batey SR, Houser TL, Donahue RM, Ascher JA. Bupropion sustained-release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatr. 2000;61:196-202.
20. Croft H, Settle E, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21: 643-58.
21. Stahl SM. Depression and bipolar disorders. In: Stahl SM, ed. Essential Psychopharmacology of Depression and Bipolar Disorder. New York: Cambridge University Press; 2000, pp. 1-63.